An early diagnosis for lung cancer can mean a cure.
Develop sensitive and
specific blood test to
Lung Cancer Proteomics has spent 13 years developing a simple blood test that can detect early stage Non-Small Cell Lung Cancer (NSCLC) with high sensitivity and specificity.
Commit to a
We focus on evaluating protein biomarkers in conjunction with proprietary algorithms and patient demographic information to provide a risk assessment for early stage lung cancer.
Simplify and improve diagnostic tools leading to
In 2016, we completed the validation of the Lung Cancer Detection Test 1 (LCDT1). The LCDT1 is a simple blood test that detects Stage 1 lung cancer with high accuracy.
Our mission is to develop sensitive and specific blood tests to detect high mortality cancers early.
We strictly adhere to a data driven approach and use rigorous scientific processes. We strive to innovate, simplify, and improve early diagnostic tools which lead to a better quality of life for cancer patients and increase survival.
Lung Cancer Proteomics, LLC
105 Washington Street
Michigan City, IN 46360
Bay Area Laboratory
780 Montague Expressway
Building 7, Suite 703
San Jose, CA 95131